Neonatal Adiposity is Largely Driven by Maternal Hyperglycemia in utero: Analysis of Routine Clinical Data from a Diabetes Clinic in India

Sayali S. Deshpande-Joshi; Sonali S. Wagle-Patki; Madhura K. Deshmukh; Himangi G. Lubree; Hemant S. Damle; Suhas R. Otiv; Sanat B. Phatak; Rucha H. Wagh; K. Meenakumari; Smita N. Dhadge; Rajashree P. Kamat; Sayali G. Wadke; Deepa A. Raut; Dattatray S. Bhat; Souvik Bandyopadhyay; Chittaranjan S. Yajnik

doi:10.1101/2024.04.27.24306016

ABSTRACT

Aim To examine the effect of maternal size and degree of hyperglycemia on neonatal adiposity in the relatively thin Indian population.

Study design Analysis of routine clinical data collected in one diabetes clinic.

Methods We examined the association of maternal size (BMI) and degree of hyperglycemia (type of diabetes, type 1 being the thinnest and most hyperglycemic, type 2 and Gestational diabetes being overweight and obese but less hyperglycemic) with neonatal adiposity measurements (weight, ponderal index, abdominal circumference, and skinfold thickness) using multiple linear regression.

Results We included data on 772 pregnancies with diabetes (61 with type 1, 79 with type 2, and 632 with gestational) and 349 with normal glucose tolerance (NGT). Mothers with type 1 diabetes had the lowest BMI and highest HbA1c, however, their neonates were the most obese, centrally obese, and adipose. Compared to neonates of NGT mothers, those of mothers with type 1 diabetes were 370 g heavier, those of mothers with type 2 diabetes 265 g, and those of mothers with GDM by 200 g. Prediction models adjusted for gestational age at birth, neonatal sex, maternal age, parity, and year of birth confirmed that neonates of mothers with type 1 diabetes were the most adipose (ponderal index, abdominal circumference and skinfolds), followed serially by those of mothers with type 2 diabetes, GDM, and NGT. Compared to maternal type of diabetes, pre-pregnancy BMI and gestational weight gain (GWG) made a much smaller contribution to neonatal adiposity.

Conclusion Our findings provide a clear answer that maternal hyperglycemia rather than BMI is the primary driver of neonatal adiposity. Adequate control of maternal hyperglycemia will help control neonatal adiposity.

What is already known about this subject?

Maternal obesity and diabetes increase neonatal adiposity which contributes to bad pregnancy outcomes
Given the strong association between maternal obesity and diabetes in western populations, the dominant determinant of neonatal adiposity is difficult to assess

What is the key question?

Is maternal BMI or hyperglycemia the primary determinant of neonatal adiposity?

What are the new findings?

Indian mothers with type 1 diabetes were the thinnest and the most hyperglycemic compared to mothers with type 2 diabetes and GDM who were more obese and less hyperglycemic, providing a contrasting exposure
Neonates of mothers with type 1 diabetes were the most obese-adipose, those of mothers with type 2 diabetes and GDM were progressively less so.

How might this impact on clinical practice in the foreseeable future?

Our results clearly show that maternal hyperglycemia is the major driver of neonatal adiposity. Strict control of maternal hyperglycemia will help reduce neonatal adiposity and associated adverse outcomes

Competing Interest Statement

CSY was a visiting professor at the Danish Diabetes Academy (supported by Novo Nordisk, Denmark) and University of Southern Denmark during the conduct of the study and writing of this article. None of the authors declare any conflict of interest.

Funding Statement

The study is largely intra-murally funded. The International Atomic Energy Agency, Vienna, Austria, provided financial support for the IAEA-B12 study (15382/R0). InDiaGDM study was funded by the Department of Biotechnology, New Delhi, India (BT/IN/Denmark/02/CSY/2014). Hinduja Foundation, Mumbai, Mukul Madhav Foundation, Pune and the Nityasha Foundation, Pune provide a generous grant for treatment of patients with type 1 diabetes.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Use of the clinical data for research analysis was approved by King Edward Memorial Hospital Research Centre Pune, Ethics Committee, (DIP 2128/08-12- 2021). IAEA-B12 study (064/06-03-2006/15382/R0) and Indo-Danish study (BT/IN/Denmark/02/CSY/2014) also had King Edward Memorial Hospital Research Centre Ethics Committee approvals. Indo-Danish study was registered with the Clinical Trials Registry-India (NCT03388723). All participants signed an informed consent before participation.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

Text and tables updated to clarify. New figure added.

Data Availability

Prof. C.S.Yajnik is the guarantor of this work and as such had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Data can be requested from Prof. C.S.Yajnik by applying with a 200 word plan of analysis, data sharing is subject to KEMHRC Ethics Committee approval and Govt. of India Health Ministry Screening Committee permission.